GALT News 11.61 Galectin Therapeutics Inc (GALT)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Galectin Therapeutics Inc (GALT) 11.61 $GALT

Galectin Therapeutics doses first patient in second cohort under Phase 1 trial of GR-MD-02
M2 - Fri Apr 18, 7:15AM CDT
Therapeutics company Galectin Therapeutics (NasdaqCM:GALT) said on Thursday that it has dosed its first patient in cohort 2 of its Phase 1 clinical trial of GR-MD-02 in patients with NASH with advanced fibrosis.

Nasdaq stocks posting largest percentage increases
AP - Thu Apr 17, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:

Why Galectin Therapeutics Inc. Shares Jumped
Sean Williams, The Motley Fool - Motley Fool - Thu Apr 17, 3:15PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Galectin Thersapeutics , a clinical-stage...

Galectin Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1 Trial of GR-MD-02 for NASH With Advanced Fibrosis
GlobeNewswire - Thu Apr 17, 9:19AM CDT
Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that the first patient in cohort 2 of its Phase 1 clinical trial of GR-MD-02 in patients with NASH with advanced fibrosis has been successfully dosed with 4 mg/kg, which is double the dose given in cohort 1. Cohort 2, as with all phases of the clinical trial, was initiated in full compliance with the rules, regulations, and specific conditions set forth by the U.S. Food and Drug Administration (FDA) for this Phase 1 clinical trial. The second cohort follows highly successful results from the first cohort showing that 2 mg/kg was safe and very well tolerated, and that GR-MD-02 treatment resulted in significant improvement in multiple biomarkers of fibrosis and liver inflammation in patients with NASH with advanced fibrosis (see full results: http://galectintherapeutics.com/wp-content/up...FINAL.pdf). The remaining patients in cohort 2 are expected to be enrolled over the next few weeks and we anticipate reporting the results of cohort 2 around the end of July.

Recent Acquisitions, Trial Opinions, Upcoming Earnings, Inducement Grants, and Clinical Trial Results - Analyst Notes on Actavis, The Medicines Company, Hospira, Horizon Pharma, and Galectin
PR Newswire - Fri Apr 11, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Actavis plc (NYSE: ACT), The Medicines Company (NASDAQ: MDCO), Hospira, Inc. (NYSE: HSP), Horizon Pharma, Inc. (NASDAQ: HZNP), and Galectin Therapeutics Inc. (NASDAQ: GALT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

Treatments for Non-Alcoholic Steatohepatitis Making Clinical Strides
ACCESSWIRE - Tue Apr 08, 10:00AM CDT
WHITEFISH, MT / April 8, 2014 / There has been a disease steadily filling market headlines recently, and no; it's not cancer. It's fatty liver disease, particularly Non-alcoholic Fatty Liver Disease, or NAFLD, regarded by many as the most common non-communicable liver disease worldwide. The disease is a silent killer that often goes undetected until late stages, for which there are no FDA-approved treatments. Biotechs focusing on innovative therapies for varying stages of NAFLD are receiving plenty of deserved media coverage. Hepatology leaders in recent headlines include Intercept Pharmaceuticals, (NASDAQ: ICPT), Cempra, Inc. (NASDAQ: CEMP), MediciNova, Inc. (NASDAQ: MNOV), Galectin Therapeutics (NASDAQ: GALT) and Lumena Pharmaceuticals, a company preparing to go public.

Galectin Therapeutics (GALT) Falls: Stock Goes Down 11.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 02, 7:38AM CDT
Galectin has seen negative earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month

First Cohort Results in Galectin Therapeutics' Phase 1 Trial Reveal Biomarker Evidence of Therapeutic Effect on Fibrosis and Inflammation in NASH With Advanced Fibrosis
GlobeNewswire - Mon Mar 31, 3:37PM CDT
-- GR-MD-02 was safe and well tolerated in patients

96.5% Return Seen to Date on SmarTrend Galectin Therapeutic Call (GALT)
Comtex SmarTrend(R) - Fri Mar 28, 4:43PM CDT
SmarTrend identified an Uptrend for Galectin Therapeutic (NASDAQ:GALT) on November 25th, 2013 at $8.00. In approximately 4 months, Galectin Therapeutic has returned 96.50% as of today's recent price of $15.72.

Leading Companies Being Defined in the Hunt for a NASH Treatment
ACCESSWIRE - Thu Mar 27, 9:32AM CDT
March 27, 2014 / The race to develop a treatment for Non-Alcoholic Steatohepatitis (NASH) is getting a lot of airtime lately, pointing to the severity of the disease, poor prognosis and desperate need for a treatment. The space has only a handful of competitors, with most seeing rising valuations due to the tremendous peak sales that analysts are projecting for products that make it to market. What is particularly unique to this disease is not only the lack of any approved treatments, but also the influx of attention and growing broad body of research by companies like Intercept Pharmaceuticals (NASDAQ: ICPT), Galmed Pharmaceuticals (NASDAQ: GLMD) and Galectin Therapeutics (NASDAQ: GALT) that shows treatments are on the horizon, which gives these equities considerable upside.

Galectin Therapeutics, Inc. (GALT) in Focus: Stock Moves Up 8.84% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 26, 7:44AM CDT
Galectin Therapeutics, Inc. was a big mover last session, as the company saw its shares rise nearly 9% on the day.

Why Plug Power, Varonis Systems, and Galectin Therapeutics Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Tue Mar 25, 4:15PM CDT
It was another day of mixed data for the broad-based S&P 500 , but this time investors were able to look past recent housing weakness and latch on to improved consumer outlooks. The big driver today was the Conference Board's final...

Galectin: Mark The Date. Drug Data Are Coming And We're Selling Stock.
at The Street - Tue Mar 25, 12:29PM CDT
How to promote your stock, Galectin style.

Why Galectin Therapeutics, Inc. Shares Soared
Sean Williams, The Motley Fool - Motley Fool - Tue Mar 25, 12:09PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Galectin Therapeutics , a clinical-stage...
Scroll down for more posts ▼

Top 10 Most Recent News Articles

AMP Tests Debt Market With €1.25 Billion Green Notes

Updated Category News Views 101

Refinancing season has arrived early at Ardagh Metal Packaging, and it is carrying a hefty €1.25 billion price tag. AMP has launched senior secured floating-rate green notes, with proceeds intended to retire two batches of secured debt due in 2028 and leave additional cash on the balance sheet for general corporate purposes, including capital expenditure. This is not...

Continue Reading
Hanon's BMW Thermal Win Matters Beyond the Trophy Case Today

Updated Category News Views 96

A 16-Kilogram Box Just Grabbed the Auto Supply Chain’s Attention Hanon Systems did not win these two 2026 PACE honors by polishing up some old hose-and-valve package. Its Highly Integrated Cooling Entity, or HICE, is aimed right at a stubborn electric-vehicle problem: keeping a vehicle’s thermal systems controlled without turning the architecture into a sprawling,...

Continue Reading
Clarivate's 2026 Research List Carries a Trust Test

Updated Category News Views 183

Seven thousand ninety awards can look like a victory lap until you remember how easily raw citation counts can be gamed. Clarivate’s 2026 Highly Cited Researchers list is more interesting for its insistence on screening than for the familiar names at the top. In a research world where publication volume, self-citation and paper mills have made plenty of people...

Continue Reading
Vertex Extends Genomics Pact With $220M in Potential

Updated Category News Views 54

Eight years is long enough to separate a useful science partner from a glossy slide deck, and Vertex’s decision to add four more years with Genomics deserves attention. This is not a splashy acquisition, nor is it a clean revenue number investors can plug into next quarter’s model. It is a deeper commitment to the slow, expensive, wonderfully unforgiving business of...

Continue Reading
24X Options Filing Puts Earnings Bets Before the SEC

Updated Category News Views 49

An earnings release already turns the market into a bar fight; 24X wants to put part of that fight inside a regulated binary-options contract. The Stamford-based exchange has filed a proposed rule change with the SEC for 24X Options, a facility that would offer a conventional options market alongside contracts tied to company performance targets. It is an interesting...

Continue Reading
Historic China-Russia-US Summit Aims for Global Stability

Updated Category News Views 85

The Weight of History in Shenzhen When the big players decide to talk face-to-face, it's more than just a photo op. This week in Shenzhen, the leaders of China, Russia, and the United States are doing just that. And let me tell you, it's the kind of gathering that can either stabilize the gears of global politics or grease the wheels of tension. This chinwag isn't just...

Continue Reading
Animal Parasite Market Growth Has a Resistance Catch

Updated Category News Views 156

Flea collars and cattle worms do not sound glamorous, yet this is exactly where durable animal-health revenue gets built. Wissen Research puts the global animal parasiticides market at $13.6 billion in 2026 and projects $18.6 billion by 2031, a 6.5% compound annual growth rate. That is respectable, not moonshot stuff, and frankly that is part of the appeal. Pet owners...

Continue Reading
Stitch AI Targets Banking’s Hardest Automation Gap

Updated Category News Views 25

The flashy chatbot stuff is cheap; banking permission to act is not. That is why Stitch AI’s launch deserves more attention than another vendor slapping “agentic” on a slide deck and calling it transformation. Banks do not need a machine to summarize a policy document while everyone applauds the demo. They need technology that can touch real workflows without...

Continue Reading
Caracal’s $200K VMI Pledge Targets Cadet Affordability

Updated Category News Views 217

A tuition award can still leave a brutal hole in the budget. That is the plain fact sitting underneath Caracal Products & Services’ $200,000 commitment to Virginia Military Institute. Federal ROTC scholarships can cover tuition, but VMI says room, board and quartermaster fees average about $15,000 annually. For a student who has done everything right—earned the ROTC...

Continue Reading
A Decade of Giving: Light the World Initiative's Impact

Updated Category News Views 131

The Red Kiosk Revolution It's not every day that a church initiative pops up in global conversations, but here we are—ten years into the Light the World initiative by The Church of Jesus Christ of Latter-day Saints. What's interesting is how these little kiosks, like silent ambassadors, have become a staple in 145 spots this holiday season, spanning continents. Each...

Continue Reading

Top 5 Most Recently Viewed Articles

Voltalia Partners with Retail Giants for EV Charging Stations

Updated Category News Views 165

Innovative Partnership to Enhance Electric Vehicle Charging Voltalia, a prominent name in the renewable energy sector, is making significant strides by collaborating with Auchan, DECATHLON, and Leroy Merlin. This partnership aims to deploy electric vehicle (EV) charging stations across more than 350 parking lots in France, marking a crucial step towards fostering...

Continue Reading
Khanh Phuong Morrow's Strategic Insider Move at Lantheus Holdings

Updated Category News Views 211

Khanh Phuong Morrow's Strategic Insider Decision at Lantheus Holdings In a recent filing, it was disclosed that Khanh Phuong Morrow, a Board Member at Lantheus Holdings (NASDAQ: LNTH), exercised stock options leading to a transaction valued at $0. This decision sheds light on the ongoing activities within the company and showcases the actions of key insiders....

Continue Reading
Investors Urged to Stay Informed on Organon & Co. Class Action

Updated Category News Views 170

Class Action Lawsuit Against Organon & Co. Pomerantz LLP has announced the initiation of a class action lawsuit against Organon & Co. This lawsuit primarily targets investors who have suffered losses relating to their investment in Organon (NYSE: OGN). With the launch of this lawsuit, it is essential for affected investors to understand their rights and options available...

Continue Reading
Sionna Therapeutics Faces Legal Scrutiny Amid Stock Plunge

Updated Category News Views 90

Stock Drop Sparks Legal Action August 10, 2026, wasn't exactly a banner day for Sionna Therapeutics' investors. We're talking about watching a stock nosedive by a jaw-dropping 92%, which is the kind of number that'd knock your socks off under normal circumstances. The catalyst? Some dismal results from the company's Phase 2a proof-of-concept study of SION-719 aimed at...

Continue Reading
Toll Brothers Unveils Stunning New Homes in Chapel Oaks

Updated Category News Views 221

Exciting New Model Homes at Chapel Oaks Community CHAPEL HILL, N.C. – Toll Brothers, Inc. (NYSE: TOL), a prominent name in luxury home construction, has recently announced the opening of their latest model home at the Chapel Oaks community. This new community marks a significant addition to their portfolio in the Raleigh area, providing prospective homeowners with...

Continue Reading